Governance revamp at Generate Biomedicines (NASDAQ: GENB) after IPO

Rhea-AI Filing Summary

Generate Biomedicines, Inc. has overhauled its corporate charter and bylaws in connection with completing its initial public offering. The company filed an amended and restated certificate of incorporation in Delaware that authorizes 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock and removes references to prior preferred series.

The new charter also removes stockholders’ ability to act by written consent or to call special meetings, centralizing these corporate actions in formal meeting processes. Updated bylaws establish detailed procedures for stockholder meetings, add advance notice requirements for proposals and director nominations, and align with the revised charter provisions.

Insights

Corporate governance analyst

Standard IPO governance reset expands capital structure and tightens stockholder procedures.

Generate Biomedicines has implemented a typical post-IPO governance package. The new charter authorizes a large pool of common shares and 10,000,000 undesignated preferred shares, giving the board flexibility to structure future financings or strategic instruments as needed.

The removal of stockholder action by written consent and limits on calling special meetings shift more control to the board and the formal meeting calendar. Updated bylaws add advance notice rules for proposals and director nominations, which can shape how future stockholder campaigns are conducted under the company’s new public-company framework.

8-K Event Classification

2 items: 5.03, 9.01

2 items

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0002100782--12-31false00021007822026-02-262026-02-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2026

Generate Biomedicines, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-43165	83-1630228
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
101 South Street, Suite 900
Somerville, Massachusetts				02143
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 888 469-0055

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		GENB		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws.

As previously disclosed in the Registration Statement on Form S-1, as amended (File No. 333-293204) (the “Registration Statement”), of Generate Biomedicines, Inc. (the “Company”), and in connection with the completion of the initial public offering of the Company’s common stock (the “IPO”), the Company filed its amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware on March 2, 2026. The Company’s board of directors (the “Board”) and the Company’s stockholders previously approved the Amended and Restated Certificate to be filed in connection with, and to be effective immediately prior to, the completion of the IPO. The Amended and Restated Certificate amends and restates the Company’s existing amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company’s stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.

The foregoing description of the Amended and Restated Certificate is qualified by reference to the Amended and Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

In addition, as previously disclosed in the Registration Statement, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders, became effective as of the effectiveness of the Registration Statement. The Amended and Restated Bylaws amend and restate the Company’s bylaws in their entirety to, among other things: (i) establish procedures for the Company’s stockholders to take formal actions at meetings of stockholders; (ii) establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of the Company’s stockholders, including proposed nominations of persons for election to the Board; and (iii) conform to the amended provisions of the Amended and Restated Certificate.

The foregoing description of the Amended and Restated Bylaws is qualified by reference to the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

3.1	Amended and Restated Certificate of Incorporation of Generate Biomedicines, Inc.
3.2	Amended and Restated Bylaws of Generate Biomedicines, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Generate Biomedicines, Inc.
Date:	March 2, 2026	By:	/s/ Michael Nally
			Name: Michael Nally, M.B.A. Title: Chief Executive Officer

FAQ

What corporate changes did Generate Biomedicines (GENB) disclose in this 8-K?

Generate Biomedicines adopted an amended and restated charter and bylaws tied to its IPO. The updates expand authorized share capital, remove legacy preferred stock references, restrict written-consent actions, and add structured procedures for stockholder meetings, proposals, and director nominations.

How many shares is Generate Biomedicines now authorized to issue?

The amended charter authorizes 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock. This larger capital structure gives the board flexibility to issue additional equity or create new preferred series if needed for financing or strategic purposes.

How did Generate Biomedicines change stockholder voting rights and actions?

The new charter eliminates stockholders’ ability to act by written consent or call special meetings themselves. Instead, stockholder decisions must occur at properly called meetings, concentrating corporate decision-making within scheduled or board-authorized sessions under the revised governance framework.

What do the amended and restated bylaws of Generate Biomedicines do?

The amended bylaws overhaul meeting procedures, outlining how stockholders can take formal action at meetings. They also introduce advance notice requirements for stockholder proposals and director nominations, and align procedural details with the newly adopted amended and restated charter provisions.

Why were Generate Biomedicines’ charter and bylaws changed around its IPO?

The company tied these changes to its initial public offering, using the transition to public status to reset its governance documents. The revised charter and bylaws are designed to support life as a Nasdaq-listed company, with clearer capital structure and meeting procedures.

Does Generate Biomedicines’ new charter still reference old preferred stock series?

No. The amended and restated charter removes references to previously existing preferred stock series. It instead authorizes 10,000,000 shares of undesignated preferred stock, which the board may later classify into one or more new series under terms it approves.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-3.1 EX-3.1 65.2 KB
• EX-3.2 EX-3.2 201.4 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.3 KB